PDE5A and pulmonary arterial hypertension: However, the therapeutic effect of PDE-5 inhibitors is dependent on baseline NO expression (levels of which are typically reduced in PAH) and they are not effective in all patients [32], [33] and sometimes need to be given at doses above those licensed in order to be effective [1].